Home > List All Publishers > Espicom Healthcare Intelligence

Espicom Healthcare Intelligence

For over 15 years, Espicom has been the choice of senior personnel in industry, commerce and government for high quality, reliable and affordable business intelligence. Espicom serves the Telecommunication, Pharmaceutical, and Medical Device industries supplying, in all, more than 7,500 customers in 50 countries worldwide. Espicom is a full service information provider whose portfolio of products range from single company and market profiles to multi-access global deals for Intranets. Whatever your requirement or budget, Espicom has the information solution you need.

List of reports from Espicom Healthcare Intelligence

GE Healthcare Medical Device Company Intelligence Report 2/1/2011 \| published by: Espicom Healthcare Intelligence ... on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical ... \| more... Search inside this report	$865.00
Hologic Medical Device Company Intelligence Report 1/31/2011 \| published by: Espicom Healthcare Intelligence ... on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical ... \| more... Search inside this report	$515.00
Smiths Medical Medical Device Company Intelligence Report 1/31/2011 \| published by: Espicom Healthcare Intelligence ... on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical ... \| more... Search inside this report	$515.00
Terumo Medical Device Company Intelligence Report 1/31/2011 \| published by: Espicom Healthcare Intelligence ... on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical ... \| more... Search inside this report	$515.00
Advanced Oral & Parenteral Drug Delivery Technologies Players, Products & Prospects to 2015 1/27/2011 \| published by: Espicom Healthcare Intelligence ... employed Appraises currently available products which utilise advanced delivery platforms Examines new product developments from major specialist drug delivery companies, critically analysing their prospects Allows ready comparison on different technologies within a company’s portfolio. Please ... \| more...	$1,740.00
Global Biosimilars: Identifying 2nd Generation Opportunities 1/17/2011 \| published by: Espicom Healthcare Intelligence ... thorough review of regulation in the USA, Europe and selected markets worldwide Examination of factors such as pricing and clinician response A review of the work of 47 key companies actively developing biosimilar products worldwide \| more... Search inside this report	$2,265.00
Actavis Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Aurobindo Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Dr Reddy's Laboratories Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Gedeon Richter Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
KRKA Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Lupin Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Ranbaxy Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Ratiopharm Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Sanofi-Aventis Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Stada Arzneimittel Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Sun Pharmaceuticals Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Teva Pharmaceutical Industries Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Zydus Cadila Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Apotex Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Aspen Pharmacare Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Cipla Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Egis Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Hospira Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Impax Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00

< prev 5 6 7 8 9 10 11 12 13 14 next >